Group 1 - The company approved a profit distribution plan for the year 2024, proposing a cash dividend of RMB 0.45 per 10 shares, totaling RMB 12,287,141.82 (including tax) based on a total share capital of 273,047,596 shares as of the announcement date [1][2] - Following a share cancellation, the total share capital will be adjusted to 273,046,796 shares, but the cash dividend per share will remain unchanged [1][2] - The actual distribution will be based on the total share capital as of the record date, which is set for July 10, 2025, with the ex-dividend date on July 11, 2025 [3] Group 2 - The company will not withhold individual income tax for shareholders, and tax will be calculated based on the holding period when shares are sold [2][3] - Different tax rates will apply for overseas institutions and individual investors holding pre-IPO restricted shares, with a 10% tax rate for Hong Kong investors on fund shares [2][3] - The distribution plan is subject to adjustments if the total share capital changes before the implementation [2]

北京诚益通控制技术集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300430 证券简称：诚益通 公告编号：2025-032 1、北京诚益通控制技术集团股份有限公司（以下简称"公司"）2024 年年 度股东大会审议通过的 2024 年度利润分配方案为：拟以截至披露利润分配方案 公告日的公司总股本 273,047,596 股为基数，向全体股东每 10 股派发现金股利 人民币 0.45 元（含税），合计派发现金股利人民币 12,287,141.82 元（含税）； 2、自 2024 年度利润分配方案披露至实施期间，公司总股本因股权激励回购 注销事项由 273,047,596 股变更为 273,046,796 股，将按照每股分配金额不变， 相应调整分配总额。本次权益分派实施后计算除权除息价格时，按公司最新总股 本折算的每 10 股现金分红=现金分红总额÷总股本（含回购股份）×10 股 =12,287,105.82 元/273,046,796×10 股=0.450000 元（保留六位小数）。本次 ...

| 投资主体 | 受托方 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年化收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | | 类型 | 额（万元） | | | 益率 | | 北京诚益通控 | | | 天添利现金 | | | 2025 年 6 | 2025 年 6 | | | 制技术集团股 | 浦发银行 | 否 | | 现金管理类 | 1750 | | | 1.7%～3% | | | | | 宝 | | | 月 11 日 | 月 26 日 | | | 份有限公司 | | | | | | | | | | 北京诚益通控 | | | | | | 2025 年 6 | 2025 年 6 | 1.80%～ | | 制技术集团股 | 江苏银行 | 否 | 苏银理财恒 | 固定收益类 | 1000 | | | | | 份有限公司 | | | 源灵动 | | | 月 13 日 | 月 23 日 | 2.60% | | 北京诚益通控 制技术集团股 | | | 民生理财天 | | | 2025 年 6 ...

Group 1 - The brain-computer interface sector experienced a decline of 3.34%, ranking among the top losers in the concept sector as of the market close on June 20 [1][2] - Within the brain-computer interface sector, major companies such as Hanwei Technology, Nanjing Panda, and Aipeng Medical saw significant declines, while only two stocks, Haige Communication and ST Huatuo, recorded gains of 1.46% and 1.05% respectively [1][2] - The sector faced a net outflow of 546 million yuan from main funds, with 23 stocks experiencing net outflows, and seven stocks seeing outflows exceeding 30 million yuan [2] Group 2 - Hanwei Technology led the outflow with a net withdrawal of 133 million yuan, followed by Innovative Medical and Tom Cat with outflows of 129 million yuan and 116 million yuan respectively [2][3] - The stocks with the highest net inflows included ST Huatuo, Haige Communication, and Lepu Medical, with inflows of 58.93 million yuan, 35.06 million yuan, and 23.44 million yuan respectively [2][3] - The trading volume for Hanwei Technology was 12.95%, indicating a high turnover rate despite the decline of 6.59% in its stock price [2][3]

Group 1 - The brain-computer interface (BCI) concept has seen a significant surge, with related stocks experiencing substantial gains, including Beiyikang reaching a "30CM" limit up and Aipeng Medical hitting a "20CM" limit up [1][2] - The first humanoid robot full industry chain exhibition in China is set to take place on June 20 in Hangzhou, featuring Tesla and Yushu, showcasing advanced technologies including bionic drive and BCI [1][4] - The BCI market in China is projected to reach 5.58 billion yuan by 2027, indicating rapid growth and commercialization potential [1][6] Group 2 - Chinese concept stocks related to BCI have seen a significant rise, with companies like Aipeng Medical and Nanjing Panda Electronics experiencing limit up and substantial gains [2][3] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, targeting applications in medical rehabilitation and smart wearables [3] - The market for BCI applications is expected to reach hundreds of billions of dollars, driven by various favorable developments and advancements in technology [4][6] Group 3 - The global BCI market is estimated to reach between 4 billion to 145 billion dollars in the medical field by 2030-2040, with non-invasive products currently leading commercialization [5][6] - The global BCI market size reached 1.98 billion dollars in 2023, with expectations to exceed 6 billion dollars by 2028, reflecting a compound annual growth rate of 25.22% [6]

脑机接口产业快速发展 据央视网6月14日消息，近日，中国科学院脑科学与智能技术卓越创新中心联合复旦大学附属华山医院 与相关企业合作，成功开展了中国首例侵入式脑机接口的前瞻性临床试验。该成果标志着我国在侵入式 脑机接口技术上成为继美国之后，全球第二个进入临床试验阶段的国家。 中关村物联网产业联盟副秘书长袁帅向《证券日报》记者表示，从技术层面来看，此次临床试验的成功 标志着我国在侵入式脑机接口技术上实现了重大突破；从产业发展角度来看，这一成果将吸引更多的科 研资源和资金投入到脑机接口领域，促进相关产业链的完善和发展。 中国信息协会常务理事、国研新经济研究院创始院长朱克力在接受《证券日报》记者采访时表示，我国 脑机接口领域进展显著，多地政府将其纳入未来产业规划，企业积极布局，但与发达国家相比，在基础 研究、核心技术和产业规模上仍有差距，目前正处于从基础研究向临床应用转化的关键阶段，需加大研 发投入、突破技术瓶颈。 企业加大研发投入抢占机遇 随着技术向临床应用加速转化，多家上市公司持续增加脑机接口技术研发投入，探索医疗健康、娱乐等 领域应用场景。 北京诚益通（300430）控制技术集团股份有限公司近日在互动平台回答投 ...

北京诚益通控制技术集团股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、北京诚益通控制技术集团股份有限公司（以下简称"公司"）本次回购 注销限制性股票 800 股，占回购注销前公司总股本 273,047,596 股的 0.0003%， 回购价格 5.54 元/股，涉及激励对象 1 人。 证券代码：300430 证券简称：诚益通 公告编号：2025-029 2、截至本公告披露日，本次回购注销事项已在中国证券登记结算有限责任 公司深圳分公司办理完成。 3、本次回购注销完成后，公司总股本由 273,047,596 股变更为 273,046,796 股。 一、股权激励计划及本次回购注销已履行的审批程序 1、2021 年 10 月 27 日，公司召开第四届董事会第九次会议、第四届监事会 第九次会议，审议通过了《关于<北京诚益通控制工程科技股份有限公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》等议案，公司独立董事对本 次激励计划的相关议案发表了独立意见，律师出具了法律意见书。 2、202 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-028 北京诚益通控制技术集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （四）会议召开时间： 1、现场会议召开时间：2025 年 5 月 15 日 14:00； 2、网络投票时间：2025年5月15日。其中通过深圳证券交易所交易系统进行 网络投票的具体时间为：2025年5月15日上午9:15-9:25,9:30-11:30，下午 13:00-15:00。通过深圳证券交易所互联网投票系统投票的具体时间为：2025年5 月15日上午9:15至下午15:00期间的任意时间。 （五）现场会议召开地点：北京市大兴区生物医药产业基地庆丰西路 27 号 6 层会议室。 1、本次股东大会没有增加、变更、否决议案的情况； 2、本次股东大会不涉及变更前次股东大会决议。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）2024 年度股 东大会会议通知已于 2025 年 4 月 24 日以公告形式发出。本次会议采取现场投票 和网络投票相结合的方式召开，现 ...

北京市朝阳区东三环中路 5 号财富金融中心 3、11、12 层（100020） 电话：+86 10 6502 8888 传真：+86 10 6502 8866 www.hylandslaw.com 法律意见书 致：北京诚益通控制技术集团股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》《上市公司股东 会规则》《北京诚益通控制技术集团股份有限公司章程》（以下简称"《公司章 程》"）的规定，北京本所律师事务所接受北京诚益通控制技术集团股份有限公 司（以下简称"公司"）委托，指派穆铁虎律师、郑玲玲律师（以下简称"本所 律师"）出席公司 2024 年度股东大会会议，并对本次股东大会会议的相关事项 依法进行见证。 为出具本法律意见书，本所律师审查了公司提供的相关文件资料。现按照律 师行业的业务标准、道德规范和勤勉尽责精神，对公司本次股东大会会议的召集 召开及其他相关事项依法出具并提供如下见证法律意见： 一、本次股东大会的召集、召开程序 经查验，公司本次股东大会是由公司董事会召集召开的。关于召开本次股东 大会的通知，公司已经依规及时在深圳证券交易所网站上予以公告，本次股东大 会拟审议的议案也已充分披露。 ...

Group 1: Industry Overview - The smart manufacturing sector is experiencing a competitive landscape where international giants dominate the high-end market, while local companies seek differentiation [2][3] - The rehabilitation medical device industry faces short-term adjustment pressures but is transitioning towards quality-based competition due to stricter regulations and market purification mechanisms [3] Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 958 million, with a net profit attributable to shareholders of CNY 96.54 million [7] - Revenue from the smart manufacturing segment decreased by 21.85% year-on-year, while the rehabilitation medical segment saw a decline of 9.73% [16] Group 3: Strategic Initiatives - The company is focused on a "dual-wheel drive" strategy, enhancing its product matrix in smart manufacturing while expanding into emerging sectors like biomanufacturing and food [5][12] - In the rehabilitation medical field, the company aims to build a high-value product system and penetrate grassroots medical markets [5][12] Group 4: Product Development and Innovation - The company has established a dual-track strategy for brain-computer interface (BCI) development, focusing on both invasive and non-invasive technologies [10][11] - Three prototypes of rehabilitation devices integrating BCI technology were successfully launched in July 2024, with plans for market registration [8][9] Group 5: Market Challenges and Responses - The company faces challenges from reduced capital expenditure willingness among clients and structural demand fatigue, impacting order delivery cycles [16] - To mitigate these challenges, the company is tightening cash flow management and optimizing funding safety margins [16]